These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1706804)

  • 1. Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients.
    Jackson SH; Shepherd AM; Ludden TM; Jamieson MJ; Woodworth J; Rogers D; Ludden LK; Muir KT
    J Cardiovasc Pharmacol; 1990 Oct; 16(4):624-8. PubMed ID: 1706804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of once daily hydralazine in inadequately controlled hypertension.
    Danielson M; Kjellberg J; Ohman P; Wernersson B
    Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydralazine once daily in hypertension.
    Silas JH; Ramsay LE; Freestone S
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative bioavailability of immediate- and sustained-release hydralazine formulations.
    Ludden TM; Rotenberg KS; Ludden LK; Shepherd AM; Woodworth JR
    J Pharm Sci; 1988 Dec; 77(12):1026-32. PubMed ID: 3244106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of food on the bioavailability of "real" and "apparent" hydralazine from conventional and slow-release preparations.
    Liedholm H; Wåhlin-Boll E; Hanson A; Melander A
    Drug Nutr Interact; 1982; 1(4):293-302. PubMed ID: 6926836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on blood hydralazine levels and response in hypertension.
    Shepherd AM; Irvine NA; Ludden TM
    Clin Pharmacol Ther; 1984 Jul; 36(1):14-8. PubMed ID: 6734044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability of plasma hydralazine concentrations in male hypertensive patients.
    Ludden TM; McNay JL; Shepherd AM; Lin MS
    Arthritis Rheum; 1981 Aug; 24(8):987-93. PubMed ID: 7284051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challenge.
    Woodworth JR; Ludden TM; Ludden LK; Shepherd AM; Rotenberg KS
    J Pharm Sci; 1992 Jun; 81(6):541-2. PubMed ID: 1522491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydralazine dose-response curve analysis.
    Graves DA; Muir KT; Richards W; Steiger BW; Chang I; Patel B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):279-91. PubMed ID: 2231320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients.
    Adir J; Janda SM; Curry CL; Taylor RE; Poku CD; Rotenberg KS
    Clin Ther; 1987; 9(6):640-50. PubMed ID: 3326679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of food on the absorption of hydralazine in man.
    Walden RJ; Hernandez R; Witts D; Graham BR; Prichard BN
    Eur J Clin Pharmacol; 1981; 20(1):53-8. PubMed ID: 7308273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between hydralazine and oral nutrients in humans.
    Semple HA; Koo W; Tam YK; Ngo LY; Coutts RT
    Ther Drug Monit; 1991 Jul; 13(4):304-8. PubMed ID: 1780961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of hydralazine bioavailability by food.
    Melander A; Danielson K; Hanson A; Rudell B; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):104-7. PubMed ID: 872490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients.
    Gaynor MF; Wright GC; Vondracek S
    Ther Adv Cardiovasc Dis; 2018 Jan; 12(1):7-15. PubMed ID: 29265003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydralazine slow-release: observations on serum profile and clinical efficacy in man.
    Talseth T; Fauchald P; Pape JF
    Curr Ther Res Clin Exp; 1977 Feb; 21(2):157-68. PubMed ID: 403050
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy.
    Rezaei Z; Sharbaf FR; Pourmojieb M; Youefzadeh-Fard Y; Motevalian M; Khazaeipour Z; Esmaeili S
    Acta Med Iran; 2011; 49(11):701-6. PubMed ID: 22131238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.